Article

A Triple-Blinded Randomized Control Trial to Evaluate the Safety and Immunogenicity of Fractional Doses of COVID-19 Vaccines (ChAd0x1, AD26.COV2.S, and BNT162B2) Among Nigeria Adults: The SIFCoVAN Trial

2025-08-14

Abstract excerpt

<title>Abstract</title> <p>Background The COVID-19 pandemic posed a major public health challenge with varying devastating effects on the global community. Vaccination is the most effective measure in combating this pandemic. A major challenge, especially in resource-limited settings, was the shortage of the vaccines. However, evidence by WHO in the use of fractionated doses in combating yellow fever prompted the...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 8de9efde-2d73-5eab-89df-814e5fc1c13a
DOI: 10.21203/rs.3.rs-5466406/v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

A Triple-Blinded Randomized Control Trial to Evaluate the Safety and Immunogenicity of Fractional Doses of COVID-19 Vaccines (ChAd0x1, AD26.COV2.S, and BNT162B2) Among Nigeria Adults: The SIFCoVAN TrialDOI 10.21203/rs.3.rs-5466406/v1Read

Safety and Immunogenicity of Fractional Doses of COVID-19 Vaccines among Nigerian Adults- A Randomised Non-Inferiority trialSemantic proximity Read

Evaluation of the Safety and Immunogenicity of Different COVID-19 Vaccine Combinations in Healthy Individuals: Study Protocol for a Randomized, Subject-blinded, Controlled Phase 3 Trial [PRIBIVAC]Semantic proximity Read

Immunogenicity and safety of fractional doses of yellow fever vaccines: a randomized, double-blind, non-inferiority trialSemantic proximity Read

Efficacy and Safety of a Booster Regimen of Ad26.COV2.S Vaccine against Covid-19Semantic proximity Read

Efficacy of heterologous boosting against SARS-CoV-2 using a recombinant interferon-armed fusion protein vaccine (V-01): a randomized, double-blind and placebo-controlled phase III trialSemantic proximity Read

Safety and immunogenicity of the Ad26.COV2.S COVID-19 vaccine candidate: interim results of a phase 1/2a, double-blind, randomized, placebo-controlled trialSemantic proximity Read

Safety, reactogenicity, and immunogenicity of Ad26.COV2.S as homologous or heterologous COVID-19 booster vaccination: Results of a randomized, double-blind, phase 2 trialSemantic proximity Read

Six Month Safety and Efficacy of the BNT162b2 mRNA COVID-19 VaccineSemantic proximity Read

Projeto S: A Stepped-Wedge Randomized Trial to Assess CoronaVac Effectiveness in Serrana, BrazilSemantic proximity Read

Nature Of, Immune Reaction to and Side Effects of COVID-19 Vaccines: Synthesis of Information Including Exclusions from Ten Phase II Trials for Planning Vaccination ProgrammesSemantic proximity Read

Preliminary Efficacy of the NVX-CoV2373 Covid-19 Vaccine Against the B.1.351 VariantSemantic proximity Read

The efficacy, safety and immunogenicity Nanocovax: results of a randomized, double-blind, placebo-controlled Phase 3 trialSemantic proximity Read